United Therapeutics (UTHR) Gross Profit (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Gross Profit data on file, last reported at $648.1 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit fell 7.66% year-over-year to $648.1 million; the trailing twelve-month figure through Mar 2026 stood at $2.7 billion (up 2.99% YoY), and the FY2025 full-year result was $2.8 billion, up 8.98% from the prior year.
• Gross Profit retreated to $648.1 million in Q1 2026, from $686.8 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $711.0 million in Q2 2025 to a low of $432.7 million in Q4 2022.
• A 5-year average of $580.5 million and a median of $604.8 million in 2024 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit soared 33.04% in 2024 and dropped 7.66% in 2026, its largest moves.
• Tracing UTHR's Gross Profit over 5 years: stood at $432.7 million in 2022, then increased by 25.65% to $543.7 million in 2023, then advanced by 21.39% to $660.0 million in 2024, then gained by 4.06% to $686.8 million in 2025, then dropped by 5.63% to $648.1 million in 2026.
• Business Quant data shows UTHR's Gross Profit at $648.1 million in Q1 2026, $686.8 million in Q4 2025, and $698.6 million in Q3 2025.